The clinical trial that led to the expanded use of remdesivir for outpatient treatment showed that a 3-day course of the medication started within 7 days of COVID-19 symptom onset reduced a person’s risk of hospitalization or death by 87%.
Outpatient treatment with remdesivir requires an intravenous infusion given over at least 30 minutes daily for three days in an infusion treatment center.